Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATFurniture, Fixtures and OtherLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

CytomX Therapeutics (CTMX) Receivables - Other (2016 - 2025)

CytomX Therapeutics' Receivables - Other history spans 11 years, with the latest figure at $900000.0 for Q4 2025.

  • For Q4 2025, Receivables - Other fell 18.18% year-over-year to $900000.0; the TTM value through Dec 2025 reached $900000.0, down 18.18%, while the annual FY2025 figure was $900000.0, 18.18% down from the prior year.
  • Receivables - Other reached $900000.0 in Q4 2025 per CTMX's latest filing, down from $1.1 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $35.0 million in Q4 2022 to a low of $800000.0 in Q1 2021.
  • Average Receivables - Other over 5 years is $3.4 million, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Receivables - Other: crashed 99.0% in 2021, then surged 4275.0% in 2022.
  • A 5-year view of Receivables - Other shows it stood at $800000.0 in 2021, then soared by 4275.0% to $35.0 million in 2022, then crashed by 93.71% to $2.2 million in 2023, then crashed by 50.0% to $1.1 million in 2024, then fell by 18.18% to $900000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Receivables - Other are $900000.0 (Q4 2025), $1.1 million (Q3 2025), and $1.2 million (Q2 2025).